Regulatory delay or failure for new product launches
Heart and liver technologies require clinical studies and market approvals before broad commercialization.
- Scope
- Heart and liver product pipeline
- Materiality
- high
Xvivo Perfusion
XVIVO Perfusion is a Swedish medical technology company focused on organ preservation, assessment, and recovery for transplantation. Its business spans thoracic and abdominal transplantation technologies, organ recovery services, and digital communication tools used by transplant teams and hospitals across multiple markets.
198
10,9 %
73,8 %
3,1 %
−1,2 %
5.76
3.68
| % | |
|---|---|
| Thoracic transplantation products | 50% Products for lung and heart transplantation, including preservation and machine perfusion systems. |
| Abdominal transplantation products | 30% Liver and kidney perfusion technologies used to preserve and assess abdominal organs. |
| Organ recovery services | 15% Clinical recovery services for donor organs, including coordination and transport support. |
| Digital workflow solutions | 5% Subscription-based communication software for transplant-clinic coordination. |
XVIVO sells primarily to transplant centers, hospitals, organ procurement organizations, and clinical teams involved in...
- Transplant centersprimary
Buy perfusion systems and disposables for lung, liver, kidney, and heart transplantation to improve organ assessment and utilization.
- Hospitalsprimary
Use organ recovery services and related clinical support to manage donor organs and transplant workflows.
- Organ procurement organizationssecondary
Coordinate donor organ recovery and transport, often alongside XVIVO service teams and logistics partners.
- Transplant teams and clinical staffsecondary
Use FlowHawk and related workflow tools to coordinate communication across donor, recipient, and recovery teams.
XVIVO is headquartered in Gothenburg, Sweden and operates through subsidiaries in the US, Netherlands, Italy, France,...
- •Head office in Gothenburg, Sweden
- •Subsidiaries in the US, Netherlands, Italy, France, Brazil, Australia, China
- •Abdominal sales are primarily generated in EMEA
- •US is important for organ recovery services and future product launches
- •International footprint supports clinical adoption and regulatory execution
XVIVO’s strategy centers on expanding machine perfusion, organ recovery services, and evidence-backed technologies...
01
Broaden machine perfusion adoptionmedium-term
Installed systems drive recurring disposable sales and deepen customer relationships.
02
Expand service solutions in the USshort-term
Organ recovery services create recurring revenue and embed XVIVO in transplant workflows.
03
Launch heart and liver technologies in key marketsmedium-term
New indications enlarge the addressable market and diversify the product portfolio.
04
Strengthen clinical evidence and regulatory positioningmedium-term
Transplant products require strong clinical data and regulatory clearance to scale.
XVIVO is exposed to regulatory, clinical, and adoption risk because its products operate in a highly controlled...
Clinical evidence and adoption risk
Transplant centers require proof of safety and efficacy before changing standard practice.
- Scope
- Machine perfusion and new treatment methods
- Materiality
- high
Foreign exchange volatility
The company reports risk from a stronger SEK versus the USD and EUR.
- Scope
- International revenue and cost base
- Materiality
- medium
Healthcare funding and procurement pressure
Customer budgets and medical resource availability affect purchasing and service uptake.
- Scope
- Hospitals, transplant centers, OPOs
- Materiality
- high
Product liability and claims risk
Medical technology and organ recovery services can create damage and liability exposure.
- Scope
- Clinical use and service operations
- Materiality
- high
Goodwill impairment
Could materially affect balance sheet and earnings if expected cash flows weaken
Capitalized development costs
Affects intangible assets, amortization, and impairment risk
Revenue recognition across products, services, and SaaS
Affects quarterly comparability and recurring revenue visibility
Seasonality and quarter-to-quarter mix
Can create volatility in reported sales and margins
: 11/08/2026